Asset Details
Do you wish to reserve the book?
Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
Do you wish to request the book?
Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
2018
Overview
To investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only therapy. We analyzed data from our two randomized, controlled open-label trials. Newly diagnoses T2D patients were randomized assigned to receive either CSII therapy or Met + CSII therapy for 4 weeks. Subjects were subjected to a 4-day continuous glucose monitoring (CGM) at the endpoint. Insulin doses and GV profiles were analyzed. The primary endpoint was differences in insulin doses and GV between the two groups. A total of 188 subjects were admitted as inpatients. Subjects in metformin add-on therapy required significantly lower total, basal and bolus insulin doses than those of control group. CGM data showed that patients in Met + CSII group exhibited significant reduction in the 24-hr mean amplitude of glycemic excursions (MAGE), the standard deviation, and the coefficient of variation compared to those of control group. Our data suggest that metformin add-on to CSII therapy leads to a significant reduction in insulin doses required by T2D patients to control glycemic variations.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Blood Glucose - drug effects
/ Blood Glucose Self-Monitoring
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - drug therapy
/ Female
/ Humanities and Social Sciences
/ Humans
/ Hypoglycemic Agents - administration & dosage
/ Hypoglycemic Agents - therapeutic use
/ Insulin
/ Insulin - administration & dosage
/ Male
/ Metformin - administration & dosage
/ Science
